Pulse pressure and diabetes treatments Blood pressure and pulse pressure difference among glucose lowering modality groups in type 2 diabetes

被引:7
作者
Alemi, Hamid [1 ]
Khaloo, Pegah [1 ]
Mansournia, Mohammad Ali [2 ]
Rabizadeh, Soghra [1 ]
Salehi, Salome Sadat [1 ]
Mirmiranpour, Hossein [1 ]
Meftah, Neda [1 ]
Esteghamati, Alireza [1 ]
Nakhjavani, Manouchehr [1 ]
机构
[1] Vali Asr Hosp, Sch Med, EMRC, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran
关键词
cardiovascular safety; glibenclamide; insulin; metformin; pulse pressure; systolic and diastolic blood pressure; type 2 diabetes mellitus; CORONARY-HEART-DISEASE; CARDIOVASCULAR SAFETY; ARTERIAL STIFFNESS; GLYCEMIC CONTROL; NONDIABETIC PATIENTS; INSULIN-RESISTANCE; METFORMIN; RISK; MORTALITY; SULFONYLUREAS;
D O I
10.1097/MD.0000000000009791
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with higher pulse pressure. In this study, we assessed and compared effects of classic diabetes treatments on pulse pressure (PP), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in patients with type 2 diabetes. In a retrospective cohort study, 718 non-hypertensive patients with type 2 diabetes were selected and divided into 4 groups including metformin, insulin, glibenclamide+metformin, and metformin+insulin. They were followed for 4 consecutive visits lasting about 45.5 months. Effects of drug regimens on pulse and blood pressure over time were assessed separately and compared in regression models with generalized estimating equation method and were adjusted for age, duration of diabetes, sex, smoking, and body mass index (BMI). Studied groups had no significant change in PP, SBP, and DBP over time. No significant difference in PP and DBP among studied groups was observed (PP: P=0.090; DBP: P=0.063). Pairwise comparisons of PP, SBP, and DBP showed no statistically significant contrast between any 2 studied groups. Interactions of time and treatment were not different among groups. Our results demonstrate patients using metformin got higher PP and SBP over time. Averagely, pulse and blood pressure among groups were not different. Trends of variation in pulse and blood pressure were not different among studied diabetes treatments.
引用
收藏
页数:7
相关论文
共 56 条
[41]   EFFECT OF INSULIN THERAPY ON BLOOD-PRESSURE IN NIDDM PATIENTS WITH SECONDARY FAILURE [J].
RANDEREE, HA ;
OMAR, MAK ;
MOTALA, AA ;
SEEDAT, MA .
DIABETES CARE, 1992, 15 (10) :1258-1263
[42]   EFFECT OF INSULIN AND GLUCOSE INFUSIONS ON SYMPATHETIC NERVOUS-SYSTEM ACTIVITY IN NORMAL MAN [J].
ROWE, JW ;
YOUNG, JB ;
MINAKER, KL ;
STEVENS, AL ;
PALLOTTA, J ;
LANDSBERG, L .
DIABETES, 1981, 30 (03) :219-225
[43]   Central pulse pressure and mortality in end-stage renal disease [J].
Safar, ME ;
Blacher, J ;
Pannier, B ;
Guerin, AP ;
Marchais, SJ ;
Guyonvarc'h, PM ;
London, GM .
HYPERTENSION, 2002, 39 (03) :735-738
[44]   Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors [J].
Safar, ME .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2001, 10 (02) :257-261
[45]   Pulse Pressure, Arterial Stiffness, and End-Organ Damage [J].
Safar, Michel E. ;
Nilsson, Peter M. ;
Blacher, Jacques ;
Mimran, Albert .
CURRENT HYPERTENSION REPORTS, 2012, 14 (04) :339-344
[46]   Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study [J].
Schram, MT ;
Kostense, PJ ;
van Dijk, RAJM ;
Dekker, JM ;
Nijpels, G ;
Bouter, LM ;
Heine, RJ ;
Stehouwer, CDA .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1743-1751
[47]   Insulin Dose and Cardiovascular Mortality in the ACCORD Trial [J].
Siraj, Elias S. ;
Rubin, Daniel J. ;
Riddle, Matthew C. ;
Miller, Michael E. ;
Hsu, Fang-Chi ;
Ismail-Beigi, Faramarz ;
Chen, Shyh-Huei ;
Ambrosius, Walter T. ;
Thomas, Abraham ;
Bestermann, William ;
Buse, John B. ;
Genuth, Saul ;
Joyce, Carol ;
Kovacs, Christopher S. ;
O'Connor, Patrick J. ;
Sigal, Ronald J. ;
Solomon, Sol .
DIABETES CARE, 2015, 38 (11) :2000-2008
[48]   Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes [J].
Skov, Vibe ;
Cangemi, Claudia ;
Gram, Jeppe ;
Christensen, Mette M. ;
Grodum, Ellen ;
Sorensen, Ditte ;
Argraves, W. Scott ;
Henriksen, Jan E. ;
Rasmussen, Lars M. .
DIABETES CARE, 2014, 37 (03) :760-766
[49]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[50]   A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes [J].
Sutton, MS ;
Rendell, M ;
Dandona, P ;
Dole, JF ;
Murphy, K ;
Patwardhan, R ;
Patel, J ;
Freed, M .
DIABETES CARE, 2002, 25 (11) :2058-2064